Currently, AAT deficiency is treated with AAT augmentation therapy, with patients receiving well tolerated weekly infusions of plasma-purified AAT that increase circulating and airway levels of AAT3. Here, SERPINA1 is linked to alpha 1-antitrypsin deficiency.